Grace Therapeutics, Inc. Write off of Deferred Debt Issuance Cost
Grace Therapeutics, Inc. (GRCE) reported Write off of Deferred Debt Issuance Cost of $264.00 thousand for the 12-month period ending 2021-03-31, per its 10-K filed 2022-06-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2022-06-21
- Grace Therapeutics, Inc. write off of deferred debt issuance cost for fiscal 2021 was $264.00K.
| Period end | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|
| 2021-03-31 | $264.00K 10-K · filed 2022-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |